三阴性乳腺癌
乳腺癌
生物标志物
免疫组织化学
癌症研究
肿瘤微环境
肿瘤科
生物
单变量分析
免疫系统
癌症
医学
内科学
免疫学
多元分析
生物化学
作者
Xinhua Yang,Xuelian Zheng,Xue‐jia Zhai,Tao Tang,Shicang Yu
标识
DOI:10.1002/prca.202300002
摘要
Abstract Background Triple‐negative breast cancer (TNBC) has a poor prognosis, an ineffective diagnosis, and a high degree of aggressiveness. Therefore, novel therapeutic targets for TNBC urgently need to be identified. Methods Through a series of bioinformatics analyses, including analysis of differential gene expression, protein‐protein interaction (PPI) network, univariate cox regression, immune infiltration, pathway enrichment, etc, as well as auxiliary immunohistochemistry (IHC) and protein quantitativae analysis, to explore prognostic marker for TNBC. Results In TNBC tissues, we found that SPDL1 (CCDC99) was considerably overexpressed at both the mRNA and protein levels compared to that in normal and non‐TNBC tissues. Additionally, we found that SPDL1‐high expression was strongly linked to poor prognosis in TNBC patients. Excessive SPDL1 expression was positively correlated with tumor growth and strongly linked to the cell cycle, DNA replication, and the p53 signaling pathway. In addition, CIBERSORT analysis revealed that SPDL1 can affect the tumor immune microenvironment (TME) in TNBC, encourage the development of TNBC and act as a potential prognostic biomarker for TNBC. Patients with SPDL1‐high expression were more sensitive to AZD8055. Notably, we discovered that SPDL1 is highly expressed in the majority of malignancies and may have an impact on the pancancer prognosis. Conclusions SPDL1 can serve as a novel prognostic marker for TNBC and pancancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI